Open AccessIs Switzerland Still a Lucrative Place for Manufacturers of Drug Substances to Produce Their Products?
Author(s) -
Hans-Dieter Bäuerle
Publication year - 2005
Publication title -
chimia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.387
H-Index - 55
eISSN - 2673-2424
pISSN - 0009-4293
DOI - 10.2533/000942905777676894
Subject(s) - business , order (exchange) , pharmaceutical industry , process (computing) , marketing , industrial organization , commerce , operations management , engineering , computer science , microbiology and biotechnology , finance , biology , operating system
Pharmaceutical manufacturers are coming under increasing pricing pressure as a result of healthcare reforms and are therefore looking to low wage countries in the Far East. Often, the outcome is a process that is not fully mature in economic terms. Contract synthesis manufacturers, such as Siegfried, offer assistance here with its comprehensive pharmaceutical know-how in order to establish efficient and low-cost processes at an early stage. Siegfried's strengths lie in its many years experience in the pharmaceutical industry and in the network of contacts it has built up over the years with technical and material suppliers. Therefore, as far as Switzerland as a location for manufacturing is concerned, Siegfried looks to the future with confidence.